7148 DPHARMA
- 1.200
- -0.020-1.64%
DPHARMA News
Malaysia Closing Bell on 27 May | DIALOG Was the Top Gainer of FBM KLCI
DIALOG was the top gainer, rising 2.00 percent to close at RM 2.550. The top loser was SIME, losing 4.07 percent to end at RM 2.830.
Duopharma's Attributable Income Shrinks in Q1; Shares Down 2%
DuoPharma (KLSE:DPHARMA) booked an attributable income to shareholders of 11.9 million ringgit in Q1, compared with 13.6 million ringgit in the year ago period, according to a filing with the Malaysia
Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Are Sitting on a Loss of 42% If They Invested Three Years Ago
Duopharma's 1Q Net Profit Down 33% on Higher Costs, Unfavorable Exchange Rates
Duopharma Biotech Bhd’s (KL:DPHARMA) net profit dropped 32.5% for the first quarter amid lower demand in the prescription pharmaceutical products, higher costs as well as unfavorable exchange rates.
Malaysia Closing Bell on 21 May | TM Was the Top Gainer of FBM KLCI
TM was the top gainer, rising 3.67 percent to close at RM 6.490. The top loser was KLK, losing 3.74 percent to end at RM 21.600.
Duopharma Biotech Clinches MYR578 Million Supply Deals
Duopharma Biotech (KLSE:DPHARMA), through two wholly-owned subsidiaries, accepted 11 letters of offers from Pharmaniaga Logistics worth an aggregate 578 million ringgit for the supply of pharmaceutica
While Individual Investors Own 28% of Duopharma Biotech Berhad (KLSE:DPHARMA), Sovereign Wealth Funds Are Its Largest Shareholders With 51% Ownership
Malaysian Firms Clinch RM28.65 Mln Potential Sales at SeaCare 2024 - MATRADE
Malaysia Closing Bell on 17 Apr | AXIATA Was the Top Gainer of FBM KLCI
AXIATA was the top gainer, rising 4.00 percent to close at RM 2.600. The top loser was PPB, losing 1.52 percent to end at RM 15.540.
Malaysia Closing Bell on 12 Apr | HLBANK Was the Top Gainer of FBM KLCI
HLBANK was the top gainer, rising 0.62 percent to close at RM 19.460. The top loser was AXIATA, losing 1.91 percent to end at RM 2.570.
Are Duopharma Biotech Berhad's (KLSE:DPHARMA) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Malaysia Closing Bell on 18 Mar | MRDIY Was the Top Gainer of FBM KLCI
18 Mar 2024 Monday FBMKLCI: 1553.640 (+0.05%) FBM70: 15715.450 (+0.32%) FBM SCAP: 16945.650 (+0.10%) FBM Emas Index: 11557.370 (+0.12%)
Duopharma Biotech's Profit Plummets in Q4 2023
Duopharma Biotech (KLSE:DPHARMA) posted a profit attributable to owners of 8.5 million ringgit in the fourth quarter of 2023, plunging from 17.2 million ringgit a year earlier. Earnings per share drop
Duopharma Biotech Issues Further Islamic Debt Worth MYR29 Million
Duopharma Biotech (KLSE:DPHARMA) issued further Islamic debt or Sukuk Wakalah worth 29 million ringgit under the Sukuk Wakalah Program. The debt securities have tenures of seven and 10 years, accordin
Duopharma Biotech Berhad's (KLSE:DPHARMA) Investors Will Be Pleased With Their Decent 80% Return Over the Last Five Years
Duopharma Biotech's Profit Drops in Q3
Duopharma Biotech (KLSE:DPHARMA) posted a profit attributable to owners of 9 million ringgit in the third, plunging from 16.3 million ringgit a year earlier. Earnings per share dropped to 0.0093 ringg
MY Morning Wrap | Anwar: Govt Dedicated to Facilitating EV Industry Growth
Stocks to watch: F&N.
Duopharma Biotech Malaysia 3rd-Quarter 2023 Earnings Summary Table
Duopharma Biotech (7148.KU) - Malaysia (3rd) quarter ended Sep 30: Figures Are In Ringgit (MYR). 2023 2022 Revenue
MY Morning Wrap | LPI Capital Records Net Profit of RM97.37mil in 3Q, Up 23% YoY
Stocks to watch: Frontken, LPI Capital.
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005
Analysis
Price Target
No Data
